Provera is a brand name for tablets that contain medroxyprogesterone as the active ingredient. It belongs to the women’s health therapeutic category and is formulated as a pill available in 5 mg and 10 mg strengths. In Hong Kong the product is classified as a prescription-only medication and is regulated by the Department of Health. Provera is historically marketed by Pfizer and is prescribed for a range of menstrual and hormonal disorders.
Medroxyprogesterone is a synthetic analogue of the natural hormone progesterone. After oral ingestion, the drug is absorbed into the bloodstream and binds to progesterone receptors in the uterus, breast, and other target tissues.
Provera is approved by regulatory agencies for several indications within women’s health:
These uses are based on clinical data reviewed by the Hong Kong Department of Health and align with international labeling.
Disclaimer: Off-label use requires individualized medical supervision and a risk-benefit assessment by a qualified healthcare professional.
If you are taking other medications, supplements, or herbal products, discuss them with your healthcare provider before starting Provera.
Note: The exact regimen must be individualized by a qualified healthcare professional based on your medical history and treatment goals.
This article provides educational information about Provera and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
Medroxyprogesterone can suppress ovulation at higher doses, but the oral tablet formulation is not approved for routine contraception. Off-label contraceptive use is occasionally reported under specialist supervision, but reliable birth-control methods should be chosen from products that carry explicit contraceptive labeling.
Heavy or prolonged bleeding may indicate a serious adverse event such as endometrial hyperplasia or a coagulation problem. Contact your healthcare provider promptly for assessment; emergency care is warranted if bleeding is rapid or accompanied by dizziness.
Most patients notice cycle regulation within one to two menstrual cycles after completing a standard 10-day regimen. Individual response varies, and persistent irregularities should be evaluated by a clinician.
Provera does not directly affect blood pressure, but it can cause fluid retention in some individuals. Regular blood pressure monitoring is advisable, and any significant changes should be discussed with your prescriber.
Yes, provided you carry the medication in its original packaging with the prescription label. Some countries may require a doctor’s note; verify travel regulations for Hong Kong residents before departure.
Because medroxyprogesterone alters progesterone levels, it can interfere with assays that measure endogenous hormone concentrations. Inform the laboratory of your medication use to interpret results accurately.
Common excipients include lactose, magnesium stearate, and microcrystalline cellulose. Patients with lactose intolerance or hypersensitivity to these components should discuss alternatives with their pharmacist.
Progesterone analogues may stimulate hormone-sensitive breast tissue. Women with a personal or family history of estrogen- or progesterone-receptor-positive breast cancer should avoid Provera unless a specialist explicitly recommends it.
Do not flush tablets down the toilet. Return them to a pharmacy take-back program or follow Hong Kong’s household waste disposal guidelines for medicines, placing tablets in a sealed container before discarding.
St. John’s wort induces CYP3A4 enzymes, potentially reducing medroxyprogesterone levels and diminishing therapeutic effect. Discuss any herbal or over-the-counter products with your healthcare provider before starting Provera.
